Eli Lilly and Company announces the launch of new indications for "ramoxiuximab"

On August 23, CDE's official website showed that Eli Lilly's new indication for Ramoxiuximab was declared for marketing (acceptance number: JXSS2101017)

Ramoxicamab is a human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit the activation of VEGFR-2, thereby inhibiting ligand-induced endothelial cell proliferation and migration.

The Insight database shows that ramucirumab was first approved by the FDA for marketing on November 5, 2014, under the trade name CYRAMZA

From the Insight database (http://db.

Since its approval to go public, its sales have continued to grow, and the Insight database shows that its sales have exceeded 1 billion yuan in 2020

From the Insight database (http://db.

In China, Eli Lilly submitted a clinical application for this product as early as 2010

Timeline of Remoluzumab Project

The status of the clinical trials of ramucirumab in China

From the Insight database (http://db.

However, Eli Lilly's original research product has not yet been launched, and domestic biosimilar drug companies are already eager to try

Ramucirumab biosimilars that have entered phase I clinical trials in China ( click here for details )

From the Insight database (http://db.